Interstitial lung disease in systemic sclerosis

Internal and Emergency Medicine

Volumn 2, Issue 4, 2007, Pages 250-255

  Kaloudi, O ^a   Miniati, I ^a,b   Alari, S ^a   Matucci Cerinic, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Interstitial lung disease; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; DIAGNOSTIC AGENT; TECHNETIUM;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; METABOLISM; PATHOPHYSIOLOGY; RADIOGRAPHY; RISK FACTOR; SCINTISCANNING; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE; HUMANS; LUNG DISEASES, INTERSTITIAL; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TECHNETIUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37749049452     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0075-1     Document Type: Article

References (48)

1. Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283-1289
2. D'Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428-440
3. Rossi GA, Bitterman PB, Ferrans VJ, Crystal RG (1985) Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Resp Dis 131:612-617
4. Manoussakis MN, Constantopoulos SH, Gharoni AE, Moutsopoulos HM (1987) Pulmonary involvement in systemic sclerosis. Chest 92:509-513
5. Steen VA, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125-131
6. Visscher DW, Myers JL (2006) Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:322-329
7. Travis WD, King TE Jr, Bateman ED et al (2002) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 165:277-304
8. Kim DS, Yoo B, Lee JS (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is non specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19:121-127
9. Bouros D, Wells AU, Nicholson AG (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Resp Crit Care Med 165:1581-1586
10. Fujita J, Yoshinouchi T, Ohtsuki Y et al (2001) Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 60:281-283
11. Nicholson AG, Colby TV, Dubois RM et al (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213-2217
12. Flaherty KR, Travis WD, Colby TV et al (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722-1727
13. Guttadauria M, Ellman H, Emmanuel G (1977) Pulmonary function in scleroderma. Arthritis Rheum 20:1071-1079
14. Peters-Golden M, Wise RA, Hochberg MC et al (1984) Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 77:1027-1034
15. Steen VD, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516-522
16. Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437-2444
17. Morgan C, Knight C, Lunt M et al (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 62:146-150
18. Wells AU, Hansell DM, Rubens MB et al (1997) Fibrosing alveolitis in Systemic Sclerosis: indices of lung function in relation to extend of disease in computerised tomography. Arthritis Rheum 40:1229-1236
19. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18:1520-1528
20. Remy-Jardin M, Remy J, Wallaert B (1993) Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary tests and broncho-alveolar lavage. Radiology 188:499-506
21. Ooi GC, Mok MY, Tsang KW (2003) Interstitial lung disease in systemic sclerosis. Acta Radiol 44:258-264
22. Desai SR, Veeraraghavan S, Hansell DM (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non specific interstitial pneumonia. Radiology 232:560-567
23. O'Brodovich H, Coates G (1987) Pulmonary clearance of 99mTC-DTPA: a non invasive assessment of epithelial integrity. Lung 166:1-16
24. Pantin CF, Valid SO, Sweatman M et al (1988) Measures of the inflammatory response in cryptogenetic fibrosing alveolitis. Am Rev Respir Dis 138:1234-1241
25. Mogulkoc N, Brutsche MH, Bishop PW et al on behalf of the Greater Manchester Pulmonary Fibrosis Consortium (2001) Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56:916-923
26. Wells AU, Hansell DM, Harisson NK et al (1993) Clearance of inhaled 99mTC predicts the clinical course of fibrosing alveolitis. Eur Resp J 6:797-802
27. Antoniou KM, Malagari K, Tzanakis N et al (2006) Clearance of technetium-99m-DTPA and HRCT findings in the evaluation of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 6:4
28. White B, Moore WC, Wigley FM (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947-954
29. Silver RM, Miller KS, Smith EA, Schabel SI (1990) Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470-476
30. Witt C, Borgess AC, John M et al (1999) Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncholaveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 58:635-640
31. Wells AU, Hansell DM, Rubens MB et al (1994) Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 150:462-468
32. Clements P, Goldin J, Kleerup E et al (2004) Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 50:1909-1917
33. Kohno N, Akiyama M, Kyoizumi S et al (1988) Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18:203-216
34. Kohno N, Kyoizumi S, Awaya Y et al (1989) New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigene K1-6. Chest 96:68-73
35. Yamane K, Ihn H, Kubo M et al (2000) Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol 27:930-934
36. Sato S, Nagaoka T, Hasegawa M (2000) Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 200:196-201
37. Day AJ (1994) The C-type carbohydrate recognition domain (CRD) superfamily. Biochem Soc Trans 22:83-88
38. Hermans C, Bernard A (1999) Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 159:646-678
39. Honda Y, Kuroki Y, Matsutsuura E et al (1995) Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860-1866
40. Takahashi H, Kuroki Y, Tanaka K et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162:258-263
41. Yanaba K, Hasegawa M, Takehara K, Sato S (2004) Comparative study of serum surfactant protein D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 31:1112-1120
42. Kodera M, Hasegawa M, Komura K et al (2005) Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 52:2889-2896
43. American Thoracic Society (1999) Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. Am J Respir Crit Care Med 160:2104-2117
44. Kharitonov SA, Cailes JB, Black CM et al (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051-1055
45. Fajac I, Kahan A, Menkes CJ et al (1998) Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 16:547-552
46. Paredi P, Kharitonov SA, Loukides S et al (1999) Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115:1352-1356
47. Moodley YP, Lalloo UG (2001) Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung. Disease Chest 119:1449-1454
48. Matucci-Cerinic M, D'Angelo S, Denton CP et al (2003) Assessment of lung involvement. Clin Exp Rheumatol 21[3 Suppl 29]:19-23